vs
KESTRA MEDICAL TECHNOLOGIES, LTD.（KMTS）与SuperCom Ltd（SPCB）财务数据对比。点击上方公司名可切换其他公司
KESTRA MEDICAL TECHNOLOGIES, LTD.的季度营收约是SuperCom Ltd的1.6倍（$22.6M vs $14.2M），SuperCom Ltd净利率更高（37.5% vs -145.3%，领先182.8%），SuperCom Ltd自由现金流更多（$-3.6M vs $-25.6M）
Kestra Medical Technologies（KMTS）是一家专注于微创医疗器械研发、生产与商业化的医疗科技企业，核心产品覆盖介入心脏病学与结构性心脏病治疗领域，市场覆盖北美、欧洲及亚太重点区域，服务全球医疗机构与患者。
Super.com是一家总部位于美国旧金山的科技公司，由侯赛因·法扎勒和施亨利联合创立。该公司主营金融服务业务，具体涵盖会员奖励计划以及旅行预订等相关服务，在出行与消费金融领域深耕发展。
KMTS vs SPCB — 直观对比
营收规模更大
KMTS
是对方的1.6倍
$14.2M
净利率更高
SPCB
高出182.8%
-145.3%
自由现金流更多
SPCB
多$22.0M
$-25.6M
损益表 — Q2 FY2026 vs Q2 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $22.6M | $14.2M |
| 净利润 | $-32.8M | $5.3M |
| 毛利率 | 50.6% | 61.2% |
| 营业利润率 | -140.7% | 16.3% |
| 净利率 | -145.3% | 37.5% |
| 营收同比 | — | -1.5% |
| 净利润同比 | — | 79.5% |
| 每股收益（稀释后） | $-0.64 | $1.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收KMTSSPCB
| Q4 25 | $22.6M | — | ||
| Q3 25 | $19.4M | — | ||
| Q2 25 | — | $14.2M | ||
| Q2 24 | — | $14.4M | ||
| Q2 23 | — | $14.1M | ||
| Q2 22 | — | $6.3M |
净利润KMTSSPCB
| Q4 25 | $-32.8M | — | ||
| Q3 25 | $-25.8M | — | ||
| Q2 25 | — | $5.3M | ||
| Q2 24 | — | $3.0M | ||
| Q2 23 | — | $-2.6M | ||
| Q2 22 | — | $-5.2M |
毛利率KMTSSPCB
| Q4 25 | 50.6% | — | ||
| Q3 25 | 45.7% | — | ||
| Q2 25 | — | 61.2% | ||
| Q2 24 | — | 52.3% | ||
| Q2 23 | — | 27.2% | ||
| Q2 22 | — | 41.8% |
营业利润率KMTSSPCB
| Q4 25 | -140.7% | — | ||
| Q3 25 | -149.1% | — | ||
| Q2 25 | — | 16.3% | ||
| Q2 24 | — | 7.7% | ||
| Q2 23 | — | -12.2% | ||
| Q2 22 | — | -49.9% |
净利率KMTSSPCB
| Q4 25 | -145.3% | — | ||
| Q3 25 | -133.3% | — | ||
| Q2 25 | — | 37.5% | ||
| Q2 24 | — | 20.6% | ||
| Q2 23 | — | -18.3% | ||
| Q2 22 | — | -82.4% |
每股收益（稀释后）KMTSSPCB
| Q4 25 | $-0.64 | — | ||
| Q3 25 | $-0.50 | — | ||
| Q2 25 | — | $1.32 | ||
| Q2 24 | — | $1.19 | ||
| Q2 23 | — | $-10.66 | ||
| Q2 22 | — | $-1.54 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $175.4M | $15.0M |
| 总债务越低越好 | — | $23.6M |
| 股东权益账面价值 | $164.1M | $37.3M |
| 总资产 | $246.7M | $65.5M |
| 负债/权益比越低杠杆越低 | — | 0.63× |
8季度趋势，按日历期对齐
现金及短期投资KMTSSPCB
| Q4 25 | $175.4M | — | ||
| Q3 25 | $201.2M | — | ||
| Q2 25 | — | $15.0M | ||
| Q2 24 | — | $5.7M | ||
| Q2 23 | — | $1.1M | ||
| Q2 22 | — | $2.9M |
总债务KMTSSPCB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $23.6M | ||
| Q2 24 | — | $29.2M | ||
| Q2 23 | — | $32.9M | ||
| Q2 22 | — | $32.3M |
股东权益KMTSSPCB
| Q4 25 | $164.1M | — | ||
| Q3 25 | $184.2M | — | ||
| Q2 25 | — | $37.3M | ||
| Q2 24 | — | $13.8M | ||
| Q2 23 | — | $3.5M | ||
| Q2 22 | — | $3.7M |
总资产KMTSSPCB
| Q4 25 | $246.7M | — | ||
| Q3 25 | $266.3M | — | ||
| Q2 25 | — | $65.5M | ||
| Q2 24 | — | $49.6M | ||
| Q2 23 | — | $40.8M | ||
| Q2 22 | — | $42.7M |
负债/权益比KMTSSPCB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.63× | ||
| Q2 24 | — | 2.11× | ||
| Q2 23 | — | 9.49× | ||
| Q2 22 | — | 8.68× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-18.3M | $-2.2M |
| 自由现金流经营现金流 - 资本支出 | $-25.6M | $-3.6M |
| 自由现金流率自由现金流/营收 | -113.5% | -25.3% |
| 资本支出强度资本支出/营收 | 32.2% | 10.0% |
| 现金转化率经营现金流/净利润 | — | -0.41× |
| 过去12个月自由现金流最近4个季度 | — | $-14.0M |
8季度趋势，按日历期对齐
经营现金流KMTSSPCB
| Q4 25 | $-18.3M | — | ||
| Q3 25 | $-26.3M | — | ||
| Q2 25 | — | $-2.2M | ||
| Q2 24 | — | $-950.0K | ||
| Q2 23 | — | $-3.4M | ||
| Q2 22 | — | $-4.1M |
自由现金流KMTSSPCB
| Q4 25 | $-25.6M | — | ||
| Q3 25 | $-34.4M | — | ||
| Q2 25 | — | $-3.6M | ||
| Q2 24 | — | $-1.6M | ||
| Q2 23 | — | $-4.5M | ||
| Q2 22 | — | $-4.4M |
自由现金流率KMTSSPCB
| Q4 25 | -113.5% | — | ||
| Q3 25 | -177.8% | — | ||
| Q2 25 | — | -25.3% | ||
| Q2 24 | — | -10.8% | ||
| Q2 23 | — | -31.5% | ||
| Q2 22 | — | -70.4% |
资本支出强度KMTSSPCB
| Q4 25 | 32.2% | — | ||
| Q3 25 | 42.2% | — | ||
| Q2 25 | — | 10.0% | ||
| Q2 24 | — | 4.2% | ||
| Q2 23 | — | 7.4% | ||
| Q2 22 | — | 4.4% |
现金转化率KMTSSPCB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.41× | ||
| Q2 24 | — | -0.32× | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
